| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Rolapitant |
| Brand | Varuby® |
| Indication | For the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. |
| Assessment Process | |
| Rapid review commissioned | 15/05/2017 |
| Rapid review completed | 12/06/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |